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OBJECTIVE—Zinc ions are essential for the formation of
hexameric insulin and hormone crystallization. A nonsynony-
mous single nucleotide polymorphism rs13266634 in the
SLC30A8 gene, encoding the secretory granule zinc transporter
ZnT8, is associated with type 2 diabetes. We describe the effects
of deleting the ZnT8 gene in mice and explore the action of the
at-risk allele.
RESEARCH DESIGN AND METHODS—Slc30a8 null mice
were generated and backcrossed at least twice onto a C57BL/6J
background. Glucose and insulin tolerance were measured by
intraperitoneal injection or euglycemic clamp, respectively. In-
sulin secretion, electrophysiology, imaging, and the generation of
adenoviruses encoding the low- (W325) or elevated- (R325) risk
ZnT8 alleles were undertaken using standard protocols.
RESULTS—ZnT8
/ mice displayed age-, sex-, and diet-depen-
dent abnormalities in glucose tolerance, insulin secretion, and
body weight. Islets isolated from null mice had reduced granule
zinc content and showed age-dependent changes in granule
morphology, with markedly fewer dense cores but more rod-like
crystals. Glucose-stimulated insulin secretion, granule fusion,
and insulin crystal dissolution, assessed by total internal reﬂec-
tion ﬂuorescence microscopy, were unchanged or enhanced in
ZnT8
/ islets. Insulin processing was normal. Molecular mod-
eling revealed that residue-325 was located at the interface
between ZnT8 monomers. Correspondingly, the R325 variant
displayed lower apparent Zn
2 transport activity than W325 ZnT8
by ﬂuorescence-based assay.
CONCLUSIONS—ZnT8 is required for normal insulin crystalli-
zation and insulin release in vivo but not, remarkably, in vitro.
Defects in the former processes in carriers of the R allele may
increase type 2 diabetes risks. Diabetes 58:2070–2083, 2009
G
lucose and other secretagogues stimulate the
release of insulin, costored in secretory gran-
ules with Zn
2 ions, from pancreatic islet
-cells (1,2). The presence of two Zn
2 ions,
located at the center of the insulin hexamer and coordi-
nated via HisB10 and GluB13 (3), is thought to be essential
for both the normal processing and crystallization of
insulin. Moreover, zinc coreleased with insulin (4) may
play an important paracrine role in the control of glucagon
secretion in some (5,6), if not all (7), mammalian species.
ZnT8 is a member of a family of ten zinc transporters
(ZnT1–10; encoded by SLC30A1–10) thought to catalyze
the extrusion of Zn
2 from the cell cytosol into the
extracellular space or intracellular organelles (8,9).
Whereas ZnT1 is ubiquitously expressed and present at the
cell surface (10), the remaining family members are lo-
cated on intracellular organelles: notably late endosomes
(ZnT2) (11), Golgi (ZnT5–7) (12), lysosomes (10), and
synaptic vesicles (13). The roles of ZnT9 and ZnT10 (14)
remain to be established. On the other hand, zinc uptake is
mediated by members of the ZiP family (8).
With the exceptions of ZnT8 and ZnT3 (present in
specialized glutaminergic neurons) (15), most ZnT family
members are expressed in the majority of mammalian
tissues. By contrast, ZnT8 (SLC30A8) mRNA levels are 2–3
orders of magnitude higher in the islet than in all other
tissues examined (16–18), with low levels being detected
in thyroid and adrenal cortex (18). Consistent with this
restricted expression pattern, ZnT8 has been shown to be
a major autoantigen in type 1 diabetes (19). Moreover,
recent genome-wide studies (20,21) have shown that a
nonsynonymous single nucleotide polymorphism rs13266634
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2070 DIABETES, VOL. 58, SEPTEMBER 2009in the SLC30A8 gene, resulting in the replacement of
tryptophan-325 with arginine, increases the risk of type 2
diabetes (OR 1.58) possibly by decreasing insulin secre-
tion and/or proinsulin processing (22,23).
Despite its clear role in both major forms of diabetes,
the molecular and cellular mechanisms through which
ZnT8 controls -cell function remain undeﬁned. Further-
more, although ZnT8 overexpression stimulates insulin
release from INS-1 -cells (17), the importance of the
endogenous transporter has so far not been examined by
silencing or genetic ablation. We show that ZnT8 mediates
zinc uptake into insulin granules and inﬂuences insulin
storage and glucose homeostasis in vivo.
RESEARCH DESIGN AND METHODS
Generation of ZnT8
/ mice. The strategy used is described in RESULTS.
Brieﬂy, Slc30a8 knockout (ZnT8
/) mice were generated by GenOway (Lyon,
France). This involved the insertion of a LoxP site together with an FRT
(Flippase Recognition Target) ﬂanked neomycin selection cassette within
intron 1 and a single distal LoxP within the upstream exon 1 containing the
translation initiation codon.
After homologous recombination in SV129-derived ES cells at the slc30a8/
ZnT8 locus and injection into C57BL/6J blastocytes, the resulting ﬂox’d mice
were mated with CMV-Cre–expressing C57BL/6J mice. These were back-
crossed three times (Toronto) or twice (London, Grenoble) onto a C57BL6
background. Separate colonies were maintained on normal rat diet with the
fat/protein/ﬁber following contents: London, Grenoble, 2.7/14.4/4.7%; Toronto,
5.0/18.0/5.0%. Animals were continuously interbred to provide all three geno-
types. ZnT8
/ mice were viable and obtained with the expected Mendelian
frequency. Comparisons were made between sex-matched littermates unless
otherwise indicated.
Histology and immunohistochemistry. Mouse pancreata were extracted
and ﬁxed in 10% neutral balanced formalin (Sigma) at 4°C for 18 h before
dehydration and wax embedding and processing to obtain 5-m slices
(Carleton’s Histological Technique, Drury and Wallington). Nuclei and cyto-
plasm were stained with hematoxylin and eosin, respectively. Sections were
labeled with anti-insulin (1:300 dilution, Secondary-Alexa 488 1:1,000) and
antiglucagon (1:200 dilution, secondary-Alexa 568 1:1,000) and sealed using
Vector Shield Antifade Hard Set reagent (Vector Laboratories).
Brightﬁeld and combined ﬂuorescence and darkﬁeld images were captured
using a Zeiss Axiovert 200 inverted microscope with 2.5 air objective and a
1,300  1,000 pixel digital camera. Single islets within the slices were analyzed
by confocal microscopy using a Zeiss Axiovert-200 microscope with an
Improvision/Nokigawa spinning disc system running Volocity 4.0 (Improvi-
sion, Coventry, U.K.) software (24).
Human pancreata, ﬁxed in 10% (v/v) formalin, were embedded in parafﬁn
and sectioned. Sections (4 m thick) were processed for immunohistochem-
istry (25) and labeled using mouse anti-insulin (Sigma, 1:2000), mouse
antiglucagon (Sigma, 1:2000), and rabbit anti-ZnT8 (Mellitech, 1:200) and
revealed with ﬂuorescein anti-rabbit and Texas-red anti-mouse secondary
antibodies (Jackson Immunoresearch, 1:200). Images were captured using a
ﬂuorescence microscope (Leitz DMRB, Leica) and digitized using a cooled
CCD (C7780, Hamamatsu).
Human islet isolation. Islets were isolated from cadaveric donors according
to ref. 26.
Gene expression analysis: islet cell populations. - and -cell populations
were extracted from transgenic mice expressing the yellow ﬂuorescent
protein derivative Venus as described (27) (see supplemental METHODS,
available in an online appendix at http://diabetes.diabetesjournals.org/
cgi/content/full/db09-0551/DC1).
Microarray analysis was performed as described in supplemental METHODS.
Quantitative RT-PCR (qPCR) for ZnT and ZiP isoforms was performed using
SYBR Green on a 7900HT RealTime PCR system (Applied Biosystems) using
three separate cell preparations (28).
ZnT8
/ mice. Total islet RNA was isolated using TRIzol Reagent (Invitrogen,
San Diego, CA) and treated with rDNase I (Ambion, Austin, TX). Isolated RNA
(1 g) was reverse transcribed using Moloney murine leukemia virus reverse
transcriptase (Invitrogen). Details of qPCR primer design and reactions are
given in supplemental METHODS. Data were normalized to mouse -actin
mRNA.
Intraperitoneal glucose tolerance test (IPGTT). Glucose tolerance was
assessed by intraperitoneal glucose injection. Mice were fasted for 5–15 h,
weighed, and glucose (1.5 g/kg unless otherwise stated) administered via
intraperitoneal injection. Glucose in tail vein blood was measured using a
Glucometer (Accu-Check).
Euglycemic clamp. Mice were anesthetized with isoﬂurane (Abbott) and an
indwelling catheter installed into the femoral vein (29). Insulin sensitivity was
assessed 4 days after surgery (30,31).
Plasmid generation. cDNAs encoding human R325- or W325-ZnT8 were
subcloned using primers bearing c-myc tags from hZnT8 and hZnT8-R325W
EGFP fusion protein constructs (16) into plasmid pIRES2-EGFP (Clontech) or
pIRES2-dsRed2 (Invitrogen). cDNA encoding a CD38-EGFP chimaera was
generated as described under supplemental METHODS.
Expression was analyzed in INS-1(832/13) -cells transfected using Lipo-
fectamine2000 (Invitrogen) according to the manufacturers’ instructions.
Cells were visualized on a Leica SP5 laser-scanning confocal microscope.
Adenovirus construction. ZnT8-c-myc tagged-EGFP constructs were ligated
into pAdtrack-CMV at KpnI and EcoRV sites. Adenoviruses were produced as
described (32).
Islet isolation and measurement of hormone secretion and processing.
Islets were aseptically isolated by collagenase digestion of mouse pancreas (7)
and insulin (24) and glucagon (7) secretion measured in batch incubations.
Insulin processing was assessed by pulse-chase labeling with
35S-methionine
(33).
Electrophysiology. Plasma membrane potential (Vm) and whole-cell KATP
channel conductance (GKATP)o f-cells were recorded in perforated patch
conﬁguration (34). Electrical capacitance (Cm) and Ca
2 current (ICa) through
the plasma membrane of -cells were recorded in standard whole-cell
conﬁguration (24). See supplemental METHODS for further details.
Total internal reﬂection ﬂuorescence microscopy. Isolated mouse islets
were dispersed and infected with adenovirus expressing neuropeptide Y
(NPY)-Venus (100 MOI) (35) before imaging (24). Release was stimulated
using 50 mmol/l KCl, 1 mol/l forskolin, and 25 mol/l isobutyl-methylxan-
thine. Fusion events were detected by eye, and the release kinetics, deﬁned by
measuring changes in ﬂuorescence within a 5-pixel diameter circle, analyzed
using Microsoft Excel and ﬁtted where appropriate to a ﬁrst-order decay curve
using Origin 7.5 software (OriginLab, Northhampton, MA).
Measurements of intracellular free [Ca
2]. Intracellular free Ca
2 concen-
tration ([Ca
2]i) was measured at 37°C using Fura-Red (Invitrogen) as
previously described (7,24).
Transmission electron microscopy. Isolated islets were ﬁxed and analyzed
as previously described (24).
RNA interference and measurement of intracellular free Zn
2. MIN6
cells were transfected using Lipofectamine 2000 (Invitrogen) with scrambled
siRNA or siRNA against ZnT8 (5-CCGUCAUGAUCUUAAAAGAtt-3) (Am-
bion) or cotransfected with mCherry subcloned into pcDNA3.1 plasmid
(Invitrogen, a gift from Dr. H. Gaisano, Toronto) and ZnT8-R325 or -W325
p-IRES constructs. After 24–48 h, cells were processed by immunocytochem-
istry (see Fig. 8A) or loaded with 3 mol/l FluoZin-3 AM or Zinquin for 50 min
at 37°C, then incubated for 10 min without dye, in perifusion buffer containing
(mM) 130 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 5 NaHCO3, 1 glucose, 10 HEPES, pH
7.4 equilibrated with 5% CO2/95% O2. Coverslips were then transferred to an
open chamber and continuously perifused with 5 mol/l ZnSO4 in the
presence of 1 mmol/l glucose at 37°C. Membrane-permeable zinc ionophore
pyrithione and zinc chelator N,N,N,N tetrakis-(2pyridylmethyl) ethylene
diamine were used as controls. Cells were imaged with or without continuous
perifusion at 36–37°C using an Olympus BX51W1 ﬂuorescent microscope
controlled with Image Master3 software (PTI, Lawrencewille, NJ) with a
high-speed monochromator (PTI). FluoZin-3 emission was monitored using
485 nm excitation, 505 nm beam splitter, and 525 nm band-pass ﬁlter. Zinquin
emission was monitored using 365 nm excitation, 375 nm beam splitter, and
385 nm long-pass ﬁlter.
Coimmunoprecipitation. HeLa cells transfected with hZnT8-V5 and ZnT8-
EGFP were lysed 48 h posttransfection, and immunoprecipitation was per-
formed with Dynabeads Protein G (Invitrogen) coated with anti-V5 (Clontech)
or anti-EGFP (Invitrogen) antibodies.
Homology modeling. The W325 form of ZnT8 was modeled on the crystal
structure of the Escherichia coli zinc transporter YiiP (PDB accession 2QFI;
resolution 3.8Å) (36) using Modeler version 8.2 (37). Alignment of the ZnT8
and YiiP sequences, which exhibit only 19% sequence identity, was aided by
comparison of the patterns of residue conservation in closer mammalian and
bacterial homologues of these proteins, respectively, using the program
ConSeq (38,39). One hundred models were generated, and the ﬁve of lowest
energy were further analyzed using MolProbity (40). Of these shown in Fig. 6C
93% had residues in the allowed regions of the Ramachandran plot (the
corresponding ﬁgure for 2QFI was 80%). The R325 variant of ZnT8 was
generated from the model in silico using PyMOL (DeLano, W.L. The PyMOL
Molecular Graphics System, 2002, www.pymol.org), which was also used to
create the images shown in Fig. 6C.
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Instruments), CellR ˆ (Olympus), and Excel (Microsoft) software. Statistical
signiﬁcance was estimated using Student’s t test with appropriate Bonferroni
correction. Pearson correlation statistics were analyzed with Simple PCI.
RESULTS
Expression of ZnT8 in the endocrine pancreas. ZnT8
immunoreactivity was localized to both - and non–-cells
in isolated human pancreatic slices (Fig. 1A) and dis-
persed human islets (Fig. 1B) consistent with recent
ﬁndings in rat pancreas (18). ZnT8 immunoreactivity was
absent from neighboring acinar cells (Fig. 1A), in line with
expression proﬁling (17,18). ZnT8 mRNA was absent in
pancreata from neurogenin3-deleted (ngn3
/) mice,
which lack an endocrine compartment, conﬁrming restric-
tion to the latter pancreatic cell types (supplementary Fig.
1 and see ref. 41). At the mRNA level, ZnT8 was the
predominant ZnT family member in both FACS-puriﬁed -
and -cells (Fig. 1C) (27), assessed by microarray (Af-
fymetrix) analysis or quantitative PCR. Notably, in both
puriﬁed -and -cells, ZnT8 mRNA levels exceeded by
	10-fold the level of any other ZnT/slc30a family member
(Fig. 1C).
Generation and histological examination of ZnT8
/
mice. To explore the potential in vivo role of ZnT8 we
generated mice lacking the slc30a8 gene. Deletion of
exon 1 (Fig. 2A and B) led to essentially complete
ablation of ZnT8 mRNA and protein expression (Fig. 2C
and D) in isolated islets. No signiﬁcant alterations were
observed in the expression of other ZnT family members
or the most abundant -cell ZiPs (supplementary Fig. 2),
ZiP6 or -7 (Fig. 2D). Examined at 12 weeks, -cell mass
was not signiﬁcantly different between / and /
mice (Toronto colony: 3.1 
 0.3 and 3.2 
 0.2 islets/
arbitrary area unit, respectively; London colony: 0.51 

AB
Glucagon ZnT8 Glucagon/ ZnT8
Insulin ZnT8 Insulin/ ZnT8 Insulin Merge ZnT8
Glucagon Merge ZnT8
Z
n
T
 
m
R
N
A
 
(
f
o
l
d
 
β
-
a
c
t
i
n
)
 
0
β                                                    α
Z
n
t
2
.
1
Z
n
t
2
.
2
Z
n
t
3
Z
n
t
4
Z
n
t
5
Z
n
t
6
Z
n
t
8
Z
n
t
1
Z
n
t
2
.
1
Z
n
t
3
Z
n
t
4
Z
n
t
5
Z
n
t
6
Z
n
t
8
Z
n
t
2
.
2
Z
n
t
1
Z
n
t
9
Z
n
t
1
0
Z
n
t
9
Z
n
t
1
0
5.0
10.0
*
NS
C
Z
n
T
 
m
R
N
A
 
(
f
o
l
d
 
β
-
a
c
t
i
n
)
 
0
1.0
2.0
3.0
4.0 β                                                     α
Z
n
t
1
Z
n
t
2
Z
n
t
3
Z
n
t
4
Z
n
t
5
Z
n
t
6
Z
n
t
7
Z
n
t
8
Z
n
t
1
Z
n
t
2
Z
n
t
3
Z
n
t
4
Z
n
t
5
Z
n
t
6
Z
n
t
7
Z
n
t
8
Microarray
qPCR
FIG. 1. Expression of ZnT8 in human pancreatic slices (A) and dissociated islet cells (B) and in puriﬁed wild-type mouse - and -cells (C). A:
Pancreatic slices stained for ZnT8; scale bar, 50 m. Cells in which clear colocalization to non–-cells was apparent are highlighted with arrows.
Essentially identical data were obtained with isolated human islets (not shown). B: Human islets were isolated (26) and dissociated with trypsin
to allow the staining of single cells; scale bar, 5 m. C and D: Mouse pancreatic - and -cells collected by ﬂow cytometry from transgenic mice
expressing the variant yellow ﬂuorescent protein Venus under the control of the preproglucagon promoter (see supplementary METHODS). Three
separate preparations of - and -cells were analyzed by either microarray analysis (C) or qPCR (D). D: Expression is presented relative to that
of -actin measured in the same sample. Primer and probe sequences are available on request. *P < 0.05 - versus -cell normalized mRNA levels.
NS, not signiﬁcant. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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 0.03% total pancreatic surface; Fig. 3A).
Moreover, the proportions of - and -cells did not differ
between genotypes in either colony (Toronto: not
shown; London, Fig. 3B). Surprisingly, normal insulin
crystallization was not required to maintain unaltered
insulin content in the absence of ZnT8 (for isolated
FIG. 2. Generation and genotyping of ZnT8
/ mice. A: See RESEARCH DESIGN AND METHODS for further details. B: Determination of genotype was
performed on DNA tail biopsies by PCR ampliﬁcation of genomic DNA using the following primers: L2: 5-CTACTTCCATTTGTCACGTCCTG
CACG-3; F4: 5-TGAAAACGGTGGGAAGCACTTGAGG-3. The band migrating at 4,000 (4,295 bp) corresponds to the endogenous locus (in the
/ case); the band at 2,500 (2,593 bp) corresponds to the Cre-mediated excised locus. C: Western immunoblotting and immunocytochemical
analysis of mice with the indicated phenotpyes. D: qPCR analysis of ZnT8 mRNA levels in islets from 8- to 12-week-old control and ZnT8
/ and
/ mice.
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21.4 
 5.8, 18.5 
 5.7, and 13.7 
 3 ng/islet for /,
/, and /, respectively, n  5 mice/genotype).
Whereas zinc content measured with FluoZin-3 (mainly
cytosolic; see below, Fig. 8B) was not reduced in
ZnT8
/ mice (Fig. 3C), the zinc content of secretory
granules and other organelles, estimated using zinquin
(Fig. 3C) (42) or dithizone (Fig. 3D) (43) (Lemaire et al.,
unpublished data), was considerably (	70%) lowered in
ZnT8
/ islets from either colony.
Examined by transmission electron microscopy,
ZnT8
/ -cells displayed a signiﬁcantly larger number of
granules lacking a detectable dense core and an increase
in granules containing atypical, rod-shaped cores (Fig. 3E,
supplementary Figs. 5–7), suggesting altered insulin crys-
tal condensation (2). No difference in the number of
granules morphologically docked at the plasma membrane
was observed (supplementary Figs. 5F and 6F). The loss of
dense core granules became more marked with age in
Toronto mice (6 vs. 12 weeks; Fig. 3E; supplementary Figs.
5C and 6C). Proinsulin processing to split proinsulins and
the mature hormone were unaltered in ZnT8
/ mice
(London; Fig. 3F).
Glucose homeostasis and insulin secretion. Male
ZnT8
/ mice maintained on normal rat diet displayed
unaltered changes in body weight with respect to control
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FIG. 3. Pancreatic histology, zinc accumulation, and insulin processing. A: Consecutive 5-m pancreatic slices from 12-week-old wild-type or ZnT8
/
mice (London) stained by hematoxylin-eosin (Magniﬁcation 2.5); islets are circled in red. B: Confocal images of pancreatic slices stained for insulin
and glucagon (see RESEARCH DESIGN AND METHODS); scale bars, 50 m. C: Intracellular zinc concentrations were estimated in isolated islets (Toronto)
using FluoZin-3 (largely cytosolic; see Fig. 8B) or zinquin (granules; Fig. 8B). Fluorescence intensity per unit area was normalized by subtraction of
the background average intensity in an area free of cells on the same coverslip, n  4–6 islets per condition. D: Isolated islets (London) stained with
0.13 mmol/l dithizone for 5 min before imaging with a 5 objective on a Zeiss Axiovert 40 microscope; scale bar, 50 m. E: Electron micrographs of
isolated islets from ZnT8
/ animals and wild-type littermate controls at the indicated ages. Toronto (a) London (b) colonies; scale bar, 1 m. F:
Proinsulin conversion to insulin in the -cells of islets isolated from ZnT8
/ or littermate control mice (12 weeks, London). (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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Toronto colony, elevated fasting glucose levels and glu-
cose intolerance during IPGTT were apparent in male
ZnT8
/ mice at 6 but not 12 weeks (Fig. 4). Female
ZnT8
/ mice in this colony displayed normal fasting
glucose but were glucose intolerant at both ages (supple-
mentary Fig. 4). Male null mice in the London colony were
also glucose intolerant at both ages (supplementary Fig. 8)
whereas normal glucose tolerance was seen in female null
mice at 12 weeks (supplementary Fig. 8).
FIG. 4. Blood glucose homeostasis and insulin secretion in ZnT8
/ mice (Toronto) in (A–D) 6- and (E and F) 12-week-old mice. A: After a 5-h
fast, glucose (1.5 g/kg) tolerance was assessed in 6-week-old male littermates. f, / (n  12); E, / (n  8); Œ, / (n  8). **P < 0.05 for
the difference between wild-type and ZnT8
/ mice. B: Insulin levels were measured during IPGTT and the area under the curve (AUC)
determined for each genotype. Secretion of insulin (C) and glucagon (D) from freshly isolated islets. Islets were from 3–12 separate mice per
genotype. , 0 mM glucose; f, 20 mM glucose. *P < 0.05. E and F: Glucose tolerance (1.5 g/kg) assessed in 12-week-old mice as in A. NS, no
signiﬁcant difference in AUC for / or / versus / mice. f, / (n  6); E, / (n  3); Œ, / (n  4). F: Glucose-stimulated insulin
secretion assessed as in A(c). *P < 0.05, **P < 0.01, ***P < 0.001 for the indicated effects.
T.J. NICOLSON AND ASSOCIATES
DIABETES, VOL. 58, SEPTEMBER 2009 2075Whereas normal insulin sensitivity was observed in
ZnT8
/ mice (Toronto, not shown; London, supplemen-
tary Fig. 9), in vivo insulin release under IPGTT was
signiﬁcantly reduced (Fig. 4A[b]). At 12 weeks, glucose-
induced insulin secretion was signiﬁcantly enhanced in
ZnT8
/ mouse islets (Toronto; Fig. 4A[c] and B[b]),
FIG. 5. Electrophysiological changes and TIRF imaging of exocytosis in single -cells. A: Membrane potential, (B) depolarization-induced
capacitance changes, and (C)C a
2 currents recorded in pancreatic islet cells: ZnT8
/ (Œ, n  17), ZnT8
/ (, n  16), and ZnT8
/ (, n 
26) animals (London, 12 weeks). A: Mean values of the whole cell capacitance change versus time are given; data were reduced to show 200
points for clarity. The stimulation protocol is given schematically above the graph. D: TIRF images of -cells before and after stimulation;
scale bar, 5 m. Release events are indicated by an arrow. Snapshots of a single release event. a–c: Mark the points seen on the graph in
E Kinetics of NPY Venus release. Data are normalized to baseline to exclude expression artifacts. Data expressed as the average of 38 versus
43 events (6 vs. 12 separate cells for / vs. /; three separate preparations per genotype). F: Proportion of full and incomplete release
events.
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fected (Fig. 4A[d]). In islets from the London colony
examined at 12 weeks, basal insulin release was signiﬁ-
cantly enhanced (ZnT8
/ vs. wild-type) but glucose- or
C
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FIG. 6. Effect of R325W polymorphism rs13266634 on the predicted molecular structure of ZnT8 and on subcellular localization and stability. A:
Western immunoblotting of ZnT8 in mouse islets and clonal MIN6 -cells. Total lysates were separated by 10% SDS-PAGE and immunoblotted with
anti-rat/mouse ZnT8 polyclonal antibodies (Mellitech, France) or anti–-actin polyclonal antibody (43 kDa; Sigma). B: Dimer formation. Human
ZnT8-V5 and ZnT8-EGFP were transfected into HeLa cells. Forty-eight hours posttransfection, cells were lysed and subjected to immunoprecipitation
with antibodies against EGFP (upper panel)o rV 5( lower panel) tags. After washing the beads, bound proteins were eluted and subjected to
immunoblotting, probing with anti-V5 (upper; predicted molecular mass for ZnT8-V5, 46.4 kDa) or anti-EGFP (lower; predicted molecular mass for
ZnT8-EGFP, 68.2 kDa) antibodies. “NS” denotes a nonspeciﬁc band, likely derived from IgG lost from the sepharose beads. C: Modeling of ZnT8
structure based on YiiP. The human transporter was modeled using the structure of the Escherichia coli transporter YiiP (PDB accession 2QFI) as a
template. Left, upper right: Provide views of the W325 variant from the plane of the membrane and the cytoplasmic side of the membrane, respectively;
lower right, view of R325 variant from cytoplasmic side of the membrane. The likely locations of zinc ions are shown as red spheres in left, and residues
at position 325 are shown in space-ﬁlling representation in all panels. D: Western immunoblotting analysis of overexpressed ZnT8 isoforms in MIN6
cells. E: Subcellular distribution of overexpressed ZnT8 isoforms in INS-1(832/13) cells; scale bar, 5 m. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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(supplementary Fig. 8[c]).
Examined in the Toronto colony, a high-fat diet led
unexpectedly to a greater gain in body weight in ZnT8
/
than wild-type mice (supplementary Fig. 3A and C). Under
this regimen, null mice displayed elevated fasting blood
glucose (supplementary Fig. 3D) and insulin (supplemen-
tary Fig. 3F) levels. Tendencies toward abnormal glucose
tolerance, elevated glucagon levels, and decreased insulin
sensitivity were also apparent (supplementary Figs. 3B, E,
and G, respectively).
Effects of ZnT8 deletion on -cell metabolism and
exocytosis. Examined in single -cells from 12-week-old
male ZnT8
/ mice (London), no signiﬁcant loss of glu-
cose- or sulfonylurea-induced membrane depolarization
(Fig. 5A) or ATP-sensitive K
 (KATP) currents (not shown)
were apparent, indicative of normal glucose metabolism.
Similarly, depolarization-induced whole -cell capacitance
changes (Fig. 5B) and Ca
2 currents (Fig. 5C) remained
unchanged, consistent with preserved exocytosis.
To determine whether the kinetics of granule cargo
discharge may be affected by abnormal insulin crystalliza-
tion, total internal reﬂection ﬂuorescence (TIRF) analysis
of release events was performed in single islet cells
infected with adenovirus encoding neuropeptide-Y fused
to the enhanced and red-shifted variant of green ﬂuores-
cent protein, Venus (NPY-Venus) (Fig. 5D–F) (35). Exocy-
tosis was stimulated by KCl in the presence of the cAMP-
raising agents forskolin and isobutyl-methylxanthine. This
protocol maximized the number of detectable events and
ensured rapid fusion pore dilation, previously shown to
lead to “full” events in which the entire granule cargo was
released (44). In this way, crystal dissolution was expected
to be rate limiting for the dispersal of the ﬂuorescence
after fusion. No differences were obtained in the rate of
NPY-Venus diffusion (t1⁄2  0.17 
 0.02 s [/] vs. 0.17 

0.03 s [/]) suggesting that crystal dissolution was not
affected by the absence of ZnT8 (Fig. 5E and F). Moreover,
there was no difference in the number of “full” events,
leading to complete or near complete loss of granule
ﬂuorescence (Fig. 5E and F), or “partial” release events in
which granule ﬂuorescence remained after the transient
increase during fusion (Fig. 5F) (35).
Impact of type 2 diabetes polymorphisms on ZnT8
function. To assess the potential impact of replacement
of the lower-risk with the higher-risk residue at position-
325, we undertook homology modeling studies based on
the bacterial zinc transporter and ZnT homologue, YiiP. A
member of the cation diffusion facilitator transporter
family (38), YiiP reportedly functions as a dimer (36),
conﬁrming similar behavior for mammalian ZnT8 from
-cell lines migrated on SDS-PAGE as bands with apparent
molecular masses of 40 and 90 kDa and indicating the
presence of monomers and possibly an SDS-resistant
dimer (Fig. 6A) (18). To conﬁrm the existence of dimers in
living cells, we coexpressed EGFP- or V5-tagged ZnT8 in
epithelial HeLa cells and performed immunoprecipitation
experiments. Efﬁcient coprecipitation indicated the exis-
tence of the transporter as dimers (Fig. 6B). Based on the
structure of YiiP (36), the probable locations of Zn
2 ion
binding sites in both the cytoplasmic and transmembrane
domains of the ZnT8 model, the latter accessible from
extracellular/intragranular side of the membrane, were
inferred from the bacterial protein structure (Fig. 6C).
Residue-325, at the cytoplasmic “tip” of each monomer in
the homology model, forms part of the dimer interface and
in different mammalian species is occupied by lower or
higher risk (Homo sapiens), Q (rat and mouse), or higher
risk (macaque) (supplementary Fig. 10). The impact of
replacing lower with higher risk was assessed by in silico
mutagenesis and revealed minimal distortion in overall
folding (Fig. 6C). Although conﬁrmation of the precise
arrangement of this region of the protein awaits determi-
nation of the crystal structure, alignment of the ZnT8
sequence with the template structure in this region of
the homology model was supported by analysis of the
pattern of residue conservation (see RESEARCH DESIGN AND
METHODS).
To identify potential physiological differences between
-cells expressing either the low-risk or increased-risk
variants of ZnT8 we used plasmid-based transfection or
adenovirus-mediated infection to introduce either form of
the protein into -cell lines. Each isoform displayed a
similar expression level as evidenced by Western immu-
noblotting (Fig. 6D) and immunocytochemical analysis of
single cells transfected with pIRES2-based plasmids (Fig.
6E). Moreover, close subcellular colocalization with insu-
lin-containing granules, apparent for endogenous ZnT8 in
human -cells (Fig. 1B) (17), was also apparent for each of
the overexpressed c-myc–tagged variants (Pearson corre-
lation coefﬁcient 0.77 
 0.01 and 0.78 
 0.02 for higher-
and lower-risk mutants, respectively; Fig. 6E).
We next examined the effects of each ZnT8 allele on the
regulation of insulin release. No signiﬁcant differences
in glucose-stimulated insulin secretion were apparent in
INS-1(832/13) cells (Fig. 7A) or MIN6 -cells (not shown)
between cells overexpressing either the higher- or the
lower-risk variant.
Measured in the whole-cell perforated-patch conﬁgura-
tion, resting membrane potential (Vm) was identical in
MIN6 cells overexpressing either vector alone, R325-ZnT8,
or W325-ZnT8 (Fig. 7B), and the resting conductance of
ATP-sensitive K
 channels (GKATP) was also of the same
order in each case (Fig. 7B). No differences in glucose- or
KCl-induced increases in apparent intracellular free Ca
2
([Ca
2]i) were apparent between cells overexpressing R-
or W325-ZnT8 (Fig. 7C). However, overexpression of ei-
ther ZnT8 isoform signiﬁcantly potentiated [Ca
2]i in-
creases in response to elevated glucose concentrations
(Fig. 7D), suggestive of an effect of ZnT8 overexpression
on either Ca
2 channel numbers or via changes in intra-
cellular cation handling.
The effects of overexpression of either isoform on
intracellular free Zn
2 concentrations ([Zn
2]i), were next
explored using trappable intracellular Zn
2-selective dyes:
FluoZin-3, Zinquin ethyl-ester, or RhodZin3-AM (45).
Whereas FluoZin-3 (Fig. 8B) and RhodZin-3 (not shown)
were localized largely to the cytosol and nuclear compart-
ments, Zinquin displayed marked punctate staining (Fig.
8B) (46), consistent with accumulation into secretory
granules (47). We monitored zinc uptake by incubation in
the presence of a supraphysiological concentration (5–10
mol/l) of zinc ions. Suggesting that ZnT8 may mediate
uptake of Zn
2 into the cytosol as well as the secretory
granules, rates of uptake monitored with FluoZin-3 were
diminished when the endogenous transporter was silenced
(Fig. 8A). Initial rates of Zn
2 uptake were markedly
elevated after overexpression of the W- but not the R325-
ZnT8 variant as chimaeras with mCherry (Fig. 8B) consis-
tent with a higher Zn
2 transporting activity of the former.
In contrast to the c-myc–tagged chimaera (Fig. 6E), over-
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2078 DIABETES, VOL. 58, SEPTEMBER 2009FIG. 7. Effects of R325W polymorphism of ZnT8 on insulin secretion and processing and on glucose signaling. A: INS-1(832/13) cells were infected
with adenovirus encoding either EGFP only or the indicated ZnT8 isoform. Forty-eight hours later, cells were incubated for 30 min at the
indicated glucose concentrations (n  6 separate cultures from two independent experiments). B: Membrane potential and KATP channel
conductance in MIN6 cells overexpressing the indicated ZnT8 isoform (n  6 in each case) in pIRES2. C: Typical traces describing changes in
intracellular free Ca
2 ([Ca
2]i) in individual MIN6 cells overexpressing the indicated ZnT8 isoform from plasmid pIRES2, or empty vector, and
stimulated with the indicated concentrations of glucose or KCl (50 mmol/l). D: Combined data from responding cells in C. The graphs describe
the increase in cytosolic [Ca
2] as AUC after stimulation with 30 mmol/l glucose (upper panel, CTRL n  13, R325 and W325, n  8 cells) or 50
mmol/l KCl (lower panel, CTRL n  46, R325 n  45, W325 n  42). *P < 0.05, **P < 0.01 for the indicated effects.
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FIG. 8. Role of ZnT8 in cellular Zn
2 transport and effects of the R325W polymorphism. A: ZnT8 expression was reduced by RNAi as assessed by
immunocytochemical analysis of cells ﬁxed in 4% (v/v) paraformaldehyde and incubated with rabbit anti-mouse ZnT8 antibody (Mellitech,
1:3,000) and anti-rabbit–conjugated secondary antibody (1:500) plus Hoechst dye (5 g/ml) before imaging on a Zeiss Axiovert inverted optics
microscope. Zn
2 uptake into single MIN6 cells was assessed by monitoring changes in FluoZin-3 ﬂuorescence (RESEARCH DESIGN AND METHODS).
Under the conditions used in these experiments, the FluoZin-3 ﬂuorescence increase gives an almost linear readout during the perifusion with
ZnSO4. The relative rates of Zn
2 accumulation were calculated from the slopes of the corresponding ﬂuorescence changes. *P < 0.05 versus
siCon, n  5 independent experiments, 108–117 cells per condition. Calibrated resting free [Zn
2]i was 600–700 pmol/l (NS, higher vs. lower risk).
B: R325 or W325 ZnT8 were overexpressed in MIN6 cells, and transfected cells were identiﬁed by ﬂuorescence of cotransfected mCherry-
expressing vector before measurements of the initial rate of apparent Zn
2 uptake as in A.* P < 0.05 versus control or ZnT8-R, n  5 independent
experiments, 67–115 cells per condition. Zinc accumulation into granules was assessed using zinquin after incubation for4hi nt h epresence of
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labeling of the plasma membrane as well as granules (Fig.
8C), suggesting that ZnT8 was able to mediate zinc trans-
port across both membranes. Importantly, zinc accumula-
tion into granules, assessed using zinquin (Fig. 8B), was
signiﬁcantly higher for overexpressed W- versus R-ZnT8.
DISCUSSION
Impact of ZnT8 deletion on insulin release. We show
that ZnT8 is required for the normal accumulation of zinc
by -cell granules, for normal insulin crystallization and
glucose tolerance. However, the impact of ZnT8 deletion
appeared to depend subtly upon variations in genetic
background, as well as age, sex, and diet. Unexpectedly,
and for reasons that remain to be elucidated, we also show
that ZnT8 is required for normal body weight homeostasis
under metabolic (high-fat diet) stress. Whether human
carriers of the at-risk R-allele are similarly affected is
presently unknown.
Studied in male ZnT8
/ mice on a substantially C57BL6
background (Toronto colony; see RESEARCH DESIGN AND
METHODS), glucose tolerance improved with age (from 6–12
weeks). Interestingly, this change was associated with a
decrease (from 35–16%) in the number of dysmorphic,
“rod-like” granules but an increase (from 24–36%) in
electron-lucent (“empty”) granules (Fig. 3E), whereas glu-
cose tolerance normalized over the same period (Fig. 4).
By contrast, in the London colony, rod-like still predomi-
nated over electron-luscent granules in ZnT8
/ mouse
-cells at 12 weeks: glucose-stimulated insulin secretion
was not enhanced with respect to wild-type controls, and
the mice remained glucose intolerant (supplementary Fig.
8). Such observations may suggest that a preponderance
of atypical crystals, rather than their total absence, con-
tributes to abnormalities in insulin release and hence
glucose intolerance.
Surprisingly, we observed no abnormalities in insulin
processing neither in ZnT8
/ islets from the London
colony nor in islets from mice where dense cores were
essentially eliminated (Lemaire et al., unpublished data)
questioning the requirement of insulin crystallization for
this process. Likewise, the kinetics of insulin release as
assessed by TIRF microscopy were unchanged under
conditions favoring the formation of large fusion pores
(35). However, basal insulin release from ZnT8
/ islets
was enhanced (supplementary Fig 8[c]), perhaps indica-
tive of more efﬁcient release of noncrystalline (mono/
dimeric) insulin when fusion pores are small (35).
ZnT8 is expressed in -cells. We show here that ZnT8 is
expressed in the majority of -cells in both humans and
rodent islets. Nonetheless, no differences in the morphol-
ogy of -cell granules in ZnT8
/ mice were apparent (not
shown). Moreover, we observed no alterations in the
regulation by glucose of glucagon secretion from ZnT8
/
islets (Fig. 4A[d]), questioning the importance of zinc
release from -cells in the control of the latter process (7).
Activities of polymorphic variants of ZnT8. Although
polymorphisms in the ZnT8/SLC30A8 gene that alter the
risk of type 2 diabetes (20,48) are likely to have a milder
effect on glucose homeostasis than that of whole body
inactivation of slc30a8 in mice as described here, it seems
likely they may alter -cell Zn
2 content and hence the
normal storage of insulin. We also conﬁrm that this
transporter is likely to be important for the uptake of Zn
2
into granules. However, the assay for ZnT8 transporter
activity we have developed here unexpectedly revealed
that the transporter may operate in the “reverse” direction,
whereby low levels of ZnT8 on the plasma membrane also
permit inﬂux into the cell in the face of high Zn
2
concentrations. Similar bidirectional zinc transport has
also been described for ZnT5 (49).
Importantly, we show here that the at-risk R-form of
ZnT8 is less active as a zinc transporter. We also demon-
strate by molecular modeling that R325 resides at the
monomer interface, a site important for the transport
activity of YiiP and other bacterial citation diffusion facil-
itator transporters (36,50). The resultant introduction of
positive charge into this region of ZnT8, close to the
predicted sites of bound structurally important Zn
2 ions,
may be expected to affect the kinetics of Zn
2 transport
and possibly the recruitment of zinc-metallochaperones
(50). Carriers of this allele may therefore accumulate zinc,
and thus package insulin, less efﬁciently into -cell gran-
ules. Future studies, possibly using appropriately engineered
mice expressing either allelic form of the transporter, will be
needed to test this hypothesis.
The present report demonstrates that ZnT8 modulates
glucose homeostasis in mice and shows that a “high risk”
allele for type 2 diabetes displays decreased activity. Small
molecule activators that target ZnT8 may thus represent
an interesting new means to treat insulin secretory deﬁ-
ciency in this disease.
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